Histogen Inc. (HSTO): Price and Financial Metrics
GET POWR RATINGS... FREE!
HSTO POWR Grades
- HSTO scores best on the Value dimension, with a Value rank ahead of 84.01% of US stocks.
- HSTO's strongest trending metric is Quality; it's been moving down over the last 47 days.
- HSTO ranks lowest in Stability; there it ranks in the 1st percentile.
HSTO Stock Summary
- With a market capitalization of $4,745,155, HISTOGEN INC has a greater market value than just 0.33% of US stocks.
- As for revenue growth, note that HSTO's revenue has grown 209.15% over the past 12 months; that beats the revenue growth of 95.51% of US companies in our set.
- The volatility of HISTOGEN INC's share price is greater than that of 99.51% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to HSTO, based on their financial statements, market capitalization, and price volatility, are SIGA, GEOS, SPNS, ONTX, and AEIS.
- HSTO's SEC filings can be seen here. And to visit HISTOGEN INC's official web site, go to www.histogeninc.com.
HSTO Valuation Summary
- In comparison to the median Healthcare stock, HSTO's EV/EBIT ratio is 97.22% lower, now standing at 0.3.
- HSTO's EV/EBIT ratio has moved up 11.6 over the prior 111 months.
Below are key valuation metrics over time for HSTO.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| HSTO | 2022-09-01 | 1.1 | 0.3 | -0.4 | 0.3 |
| HSTO | 2022-08-31 | 1.1 | 0.3 | -0.4 | 0.3 |
| HSTO | 2022-08-30 | 1.3 | 0.3 | -0.5 | 0.3 |
| HSTO | 2022-08-29 | 1.2 | 0.3 | -0.4 | 0.3 |
| HSTO | 2022-08-26 | 1.1 | 0.3 | -0.4 | 0.3 |
| HSTO | 2022-08-25 | 1.1 | 0.3 | -0.4 | 0.3 |
HSTO Growth Metrics
- The 3 year net cashflow from operations growth rate now stands at 66.54%.
- Its 3 year price growth rate is now at -98.15%.
- Its 2 year cash and equivalents growth rate is now at 1.1%.
The table below shows HSTO's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2022-06-30 | 4.356 | -11.399 | -11.525 |
| 2022-03-31 | 4.356 | -11.265 | -11.353 |
| 2021-12-31 | 1.032 | -14.532 | -14.95 |
| 2021-09-30 | 1.505 | -15.888 | -15.323 |
| 2021-06-30 | 1.409 | -15.751 | -14.731 |
| 2021-03-31 | 1.512 | -13.012 | -21.195 |
HSTO's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- HSTO has a Quality Grade of D, ranking ahead of 11.54% of graded US stocks.
- HSTO's asset turnover comes in at 0.064 -- ranking 308th of 681 Pharmaceutical Products stocks.
- PLXP, AGTC, and LPTX are the stocks whose asset turnover ratios are most correlated with HSTO.
The table below shows HSTO's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.064 | 0.403 | -1.400 |
| 2021-03-31 | 0.080 | 0.385 | -2.095 |
| 2020-12-31 | 0.126 | 0.530 | -2.520 |
| 2020-09-30 | 0.062 | 0.633 | -4.218 |
| 2020-09-30 | 0.062 | 0.633 | -4.218 |
| 2020-06-30 | 0.190 | 0.978 | -6.396 |
HSTO Price Target
For more insight on analysts targets of HSTO, see our HSTO price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $15.00 | Average Broker Recommendation | 1.25 (Strong Buy) |
HSTO Stock Price Chart Interactive Chart >
HSTO Price/Volume Stats
| Current price | $1.87 | 52-week high | $18.40 |
| Prev. close | $1.90 | 52-week low | $1.61 |
| Day low | $1.84 | Volume | 60,344 |
| Day high | $1.91 | Avg. volume | 394,836 |
| 50-day MA | $2.46 | Dividend yield | N/A |
| 200-day MA | $4.45 | Market Cap | 4.67M |
Histogen Inc. (HSTO) Company Bio
Histogen Inc., a regenerative medicine company, develops therapies based upon the products of cells grown under simulated embryonic conditions. It offers human multipotent cell conditioned media (CCM); human extracellular matrix (hECM); and hair stimulating complex (HSC). The company's technology focuses on stimulating a patient's own stem cells by delivering a complex of multipotent human proteins that support stem cell growth and differentiation. Histogen Inc. is headquartered San Diego, California.
Latest HSTO News From Around the Web
Below are the latest news stories about HISTOGEN INC that investors may wish to consider to help them evaluate HSTO as an investment opportunity.
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on ThursdayIt's time to take a look at the biggest pre-market stock movers for Thursday and the news that's got those shares moving! |
Histogen Reports Second Quarter 2022 Financial Results and Provides Business UpdateClosed $5M Financing in July Regained Compliance with Nasdaq Minimum Bid Price Requirement SAN DIEGO, Aug. 11, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics for orthopedic indications and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today reported financial results for the second quarter ended June 30, 2022 and provided an update on it |
Histogen to Report Second Quarter 2022 Financial Results and Provide Business UpdateSAN DIEGO, July 27, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, today announced that Histogen’s financial results for the second quarter ended June 30, 2022 will be released after the close of market on Thursday, August 11, 2022. About Histogen Inc. Histogen Inc. is a clinical-stage th |
Histogen Announces Closing of $5 Million Private Placement Priced At-the-Market Under Nasdaq RulesSAN DIEGO, July 14, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced today that it has closed its previously announced private placement of 1,774,309 shares of common stock (or pre-funded warrants in lieu thereof), Series A warrants to purchase up to an aggregate of 1,774,309 shar |
Histogen Announces $5 Million Private Placement Priced At-the-Market Under Nasdaq RulesSAN DIEGO, July 12, 2022 (GLOBE NEWSWIRE) -- Histogen Inc. (NASDAQ: HSTO), a clinical-stage therapeutics company focused on developing both restorative therapeutics and pan-caspase and caspase selective inhibitors focused on treatments for infectious and inflammatory diseases, announced today that it has entered into a securities purchase agreement with a single healthcare-focused institutional investor to issue 1,774,309 shares of common stock (or pre-funded warrants in lieu thereof), Series A |
HSTO Price Returns
| 1-mo | -17.26% |
| 3-mo | -16.89% |
| 6-mo | -57.86% |
| 1-year | -88.93% |
| 3-year | -97.22% |
| 5-year | -99.84% |
| YTD | -71.90% |
| 2021 | -56.11% |
| 2020 | -81.05% |
| 2019 | -76.88% |
| 2018 | -62.55% |
| 2017 | -12.33% |
Loading social stream, please wait...